Maraviroc Market

Maraviroc Market Size, Share & Industry Analysis, By Source (Pharmaceutical Manufacturers (Branded & Generic), Contract Manufacturing Organizations (CMOs), Research-Grade Suppliers), By Key End-Use Industries (Pharmaceutical Industry, Hospitals & Clinics, Research Institutions) and Forecast, 2025-2035

The Maraviroc market is projected to grow at a CAGR of 4.9% from 2025 to 2035, driven by continued demand for innovative antiretroviral therapies and growing awareness of HIV strain resistance management. Maraviroc is a CCR5 antagonist that blocks the CCR5 co-receptor on the surface of CD4 cells, thereby preventing certain strains of HIV-1 (R5-tropic) from entering and infecting immune cells.

Regionally, North America leads the Maraviroc market due to strong HIV treatment infrastructure, early adoption of advanced therapies, and established pharmaceutical players. Europe follows, particularly in countries with structured HIV care programs and public reimbursement. The Asia-Pacific region is expected to grow significantly over the forecast period due to rising HIV incidence, improving access to diagnostics and antiretrovirals, and government-backed HIV control efforts in countries like India, Thailand, and China.

It is primarily used in combination therapy for patients with multidrug-resistant HIV or those with limited treatment options. The market is supported by increasing global initiatives to manage HIV/AIDS, the rise in late-diagnosed HIV cases requiring second-line therapies, and the potential use of Maraviroc in HIV pre-exposure prophylaxis (PrEP) studies and inflammatory disease trials. While newer drug classes have gained ground, Maraviroc maintains relevance for niche populations, especially where genotypic resistance testing identifies CCR5-tropic virus. Its role is also expanding in research on autoimmune diseases and graft-versus-host disease (GVHD).

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

Introduction

Overview of Maraviroc
Key Applications & Industry Use Cases
Market Scope & Study Objectives

Market Overview

Global Market Size & Growth Trends (Historical & Forecast)
Market Value & Revenue Analysis
Demand-Supply Dynamics

Segmental Outlook

By Source
- Pharmaceutical Manufacturers (Branded & Generic)
- Contract Manufacturing Organizations (CMOs)
- Research-Grade Suppliers
Key End-Use Industries
- Pharmaceutical Industry
- Hospitals & Clinics
- Research Institutions

Price Analysis

Current Price Trends (Per kg & Per Ton)
Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)

Production & Supply Volume

Global Production Capacity & Key Manufacturers
Production Process & Technological Developments
Raw Material Analysis

Trade Analysis (Import & Export)

Major Exporting & Importing Countries
Trade Volume & Value Statistics
Impact of Trade Regulations & Policies

Regional Analysis

North America (US and Canada)
Europe (UK, Germany, France, Italy, Spain, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
Rest of the World (Latin America, Middle East, and Africa)

Competitive Landscape

Top Global Manufacturers & Market Share
Company Profiles & Key Developments
Mergers, Acquisitions & Investments

Regulatory & Compliance Factors

FDA, REACH, and Other Regulatory Frameworks
Environmental & Safety Considerations
Emerging Policies Impacting Market Growth

Conclusion & Strategic Recommendations

Key Takeaways for Stakeholders
Market Entry Strategies

May 31, 2025

What is Maraviroc?

Maraviroc is an antiretroviral drug classified as a CCR5 antagonist used in the treatment of HIV-1 infection. It works by blocking the CCR5 co-receptor on the surface of immune cells, thereby preventing the virus from entering and infecting these cells.

What is the market growth of Maraviroc?

The global Maraviroc market is projected to grow at a CAGR of 4.9% from 2025 to 2035. Growth is supported by increasing HIV diagnosis and treatment rates, as well as the continued need for alternative therapies for patients resistant to or intolerant of first-line antiretrovirals.

What are the drivers of the Maraviroc market?

Key drivers include the persistent global HIV burden, increasing awareness of HIV tropism testing, and Maraviroc’s utility in salvage therapy for treatment-experienced patients. It also appeals to clinicians seeking mechanistically unique options for managing multidrug-resistant HIV.

Who are the key players operating in the Maraviroc market?

The primary manufacturer is Pfizer Inc., which developed and markets the drug under the brand name Selzentry (U.S.) or Celsentri (EU). Other key participants include Teva Pharmaceutical Industries, Mylan, and Cipla.

Which region will exhibit the fastest growth in the Maraviroc market?

The Asia-Pacific region is expected to show the fastest growth due to the high HIV prevalence, increasing adoption of personalized treatment regimens, and support from international initiatives like PEPFAR and The Global Fund.

$1800/- Single User License
$3600/- Multi User License

Experienced in market research and consulting.
Seasoned professionals with diverse industry knowledge.
Proven track record in delivering valuable insights.
Tailored methodologies for unique client needs.
End-to-end services: market analysis, competitor intelligence, consumer behavior, and strategic recommendations.
Latest tools and tech for data collection, analysis, and visualization.
Embrace of AI and machine learning for deeper insights.
Global capabilities and extensive network.
In-depth understanding of international markets, trends, and regulations.
Dedicated to addressing specific client needs and goals.
Focus on delivering value through efficient research outcomes.

How can we help you?

Reach out to discuss how our team can help your business achieve real results.

Contact Person

Mr. Anurag Tiwari

Call Us

+91-780-304-0404

Mail Us

info@omrglobal.com